Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduning Injection for acute exacerbation of COPD
ChiCTR-TRC-13003160Phase 4Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Reduning in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Body temperature and Clinical symptoms. Started Mar 2013; status: completed.
02
Drugs
Reduning
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR-TRC-13003160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003160.